{"id":"https://genegraph.clinicalgenome.org/r/5fea0e93-7b81-4b99-aa56-7e95f2de0222v1.0","type":"EvidenceStrengthAssertion","dc:description":"GAD1 was first reported in relation to an autosomal recessive developmental delay in 2004 (Lynex CN, et al., 2004, PMID: 15571623), in association with spastic cerebral palsy, however subsequent reports have reported epileptic encephalopathy as the predominant presentation with spasticity present in approximately half of the patients. Evidence supporting this gene-disease relationship includes case-level data, segregation data, and experimental data. At least 15 unique variants (missense, nonsense, frameshift, in-frame deletion, and splicing) have been reported in humans. Variants in this gene have been reported in at least 14 probands in 5 publications (PMIDs: 28454995, 31144778, 32282878, 15571623, 32705143). Variants in this gene segregated with disease in additional family members. This gene-disease association is supported by its function in glutamate decarboxylase activity (PMID: 1549570), its expression in the brain (PMID: 9177246), and zebrafish model (PMID: 30200754) as well as three mouse models (PMIDs: 9177246, 9326630, 20333300) that partially recapitulate disease. In summary, GAD1 is definitively associated with autosomal recessive epileptic encephalopathy.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/5fea0e93-7b81-4b99-aa56-7e95f2de0222","GCISnapshot":"https://genegraph.clinicalgenome.org/r/20fdee08-81b0-4957-a18a-8f622e0ab054","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/20fdee08-81b0-4957-a18a-8f622e0ab054_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2021-05-13T15:22:39.014Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/20fdee08-81b0-4957-a18a-8f622e0ab054_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10011","date":"2021-05-13T15:22:50.490Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20fdee08-81b0-4957-a18a-8f622e0ab054_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/20fdee08-81b0-4957-a18a-8f622e0ab054_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dd1a24c5-05a8-4a36-9b1a-c8af8efb7169","type":"EvidenceLine","dc:description":"gad1b morphant fish displayed abnormal craniofacial features, as reported in 6/14 patients. Additional features of the disease, such as epilepsy, were not reported.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2d1fac34-88f3-4dc1-a6ce-4d1863eeb72b","type":"Finding","dc:description":"Assessment of the cartilaginous head skeleton by Alcian blue staining in flat mount preparations at 7 dpf revealed defects in both the neurocranium and the pharyngeal skeleton in gad1b morphant larvae. The neurocranium includes the ethmoid plate, trabeculae and parachordal cartilages, and the pharyngeal skeleton includes cartilages of the segmented jaw, opercular, and gill-bearing skeleton","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30200754","rdfs:label":"MO Zebrafish","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/4489b07b-c2a4-44ce-8c13-d282932e7c8e","type":"EvidenceLine","dc:description":"Similar to the mouse reported PMID: 9177246, the predominant phenotype in the null mouse is cleft palate, which has also been seen in 4/14 patients. The additional phenotypes in humans such as epilepsy and developmental delay are not reported in the mouse but this may be due to the neonatal lethality.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/313dcb9f-6e25-42cb-a295-7592961e86ec","type":"Finding","dc:description":"Null mice were characterized by neonatal death and a highly penetrant cleft secondary palate.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9326630","rdfs:label":"Null mouse #2","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/36d5b0c7-c164-4048-bf67-b3014d584ca7","type":"EvidenceLine","dc:description":"The CNS-specific KO mouse also had  the predominant phenotype of cleft palate, which has also been seen in 4/14 patients. The additional phenotypes in humans such as epilepsy and developmental delay are not reported in the mouse but these were studied only as embryos.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a328443-7953-4fbd-b0d2-9cfc1fed31e8","type":"Finding","dc:description":"Found a complete cleft palate in 9 out of the 11 KO embryos as well as umbilical hernia in 6 of 11.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20333300","rdfs:label":"CNS-specific KO mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4dfd1445-6445-4de8-b839-4de1371d5c38","type":"EvidenceLine","dc:description":"The predominant phenotype in the null mouse is cleft palate, which has also been seen in 4/14 patients. The additional phenotypes in humans such as epilepsy and developmental delay are not reported in the mouse but this may be due to the neonatal lethality.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f53b9120-a8ef-4cc8-b8f0-c4296023fbe9","type":"Finding","dc:description":"These null mice have cleft palate, resulting in neonatal death, and a marked reduction of GABA in the absence of discernible structural defects in the brain.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9177246","rdfs:label":"GAD67 Null mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/20fdee08-81b0-4957-a18a-8f622e0ab054_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9e7d164-e512-4f2c-b593-0402daa42673","type":"EvidenceLine","dc:description":"Demonstrated the role of GAD1 in glutamate decarboxylase activity.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7f023b3a-0139-4984-a435-3ce812e3b9d8","type":"Finding","dc:description":"Loss of GAD1 activity likely causes a constitutive GABA deficiency with a detrimental impact on neurodevelopment, hence the developmental and epileptic encephalopathy seen in patients. While, such a GABA deficiency has been observed in mouse models it has not been measured in humans.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1549570","rdfs:label":"glutamate decarboxylase activity","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c0f6441f-20f4-4455-adef-e52b23866a69","type":"EvidenceLine","dc:description":"The expression of GAD67 in the brain is consistent with the neurological phenotypes seen in patients. This is in agreement with the expression reported in The Human Protein atlas, tissue enhanced in brain.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f90342a-de0b-403c-882b-3ac94e84b392","type":"Finding","dc:description":"In situ hybridization of WT brain tissue demonstrated the presence of GAD67 mRNA signals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9177246","rdfs:label":"in situ hybridization","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/20fdee08-81b0-4957-a18a-8f622e0ab054_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a8652c76-87d9-402b-86f3-c2eced37b29e_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous frameshift variant Gln190SerfsTer11 in exon 6 of 17 is predicted to result in NMD.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/70291740-2615-4434-8e88-6436f9aa0394","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","rdfs:label":"F:II-2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001250","obo:HP_0011182","obo:HP_0002521","obo:HP_0001263","obo:HP_0001252","obo:HP_0010864","obo:HP_0011003"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a8652c76-87d9-402b-86f3-c2eced37b29e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","allele":{"id":"https://genegraph.clinicalgenome.org/r/de2bd127-a30f-40c8-98ef-f70aef7c5ec6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.568del (p.Gln190SerfsTer11)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139532589"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ab277ef8-bd7b-4d3a-8b68-dc0fb5621e3c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous nonsense variant Tyr29Ter is predicted to result in NMD.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5a8b9e4c-bd35-4c20-951d-2b50dbe73d48","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","rdfs:label":"E:III-3","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000365","obo:HP_0002015","obo:HP_0001252","obo:HP_0010864","obo:HP_0002069","obo:HP_0001263","obo:HP_0002827","obo:HP_0030680","obo:HP_0011470","obo:HP_0001999","obo:HP_0000175","obo:HP_0011182","obo:HP_0001265"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ab277ef8-bd7b-4d3a-8b68-dc0fb5621e3c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","allele":{"id":"https://genegraph.clinicalgenome.org/r/14b4f452-5cd1-4524-bda8-0a94b6af7fc7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.87C>G (p.Tyr29Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA349270208"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8b07791d-9265-4d8c-8836-8cfd3ef7ac50_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous frameshift variant Val271AspfsTer9, in exon 8 of 17, generates a premature stop codon which is predicted to result in NMD.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6a392e44-bd6d-48a3-a0c8-3e83c7aeb467","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","rdfs:label":"Case 5: Patient C-III:1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"detectionMethod":"WGS with Sanger confirmation.","firstTestingMethod":"Whole genome shotgun sequencing","phenotypes":["obo:HP_0000405","obo:HP_0001762","obo:HP_0001945","obo:HP_0002421","obo:HP_0001250","obo:HP_0001252","obo:HP_0000175","obo:HP_0001344","obo:HP_0000817","obo:HP_0002509","obo:HP_0002187","obo:HP_0010851"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8b07791d-9265-4d8c-8836-8cfd3ef7ac50_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","allele":{"id":"https://genegraph.clinicalgenome.org/r/0d5ec08e-e9d9-45fa-be56-feb2e57d4de5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.812_816del (p.Val271AspfsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139532587"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6c0c8e3c-7d0b-434b-b410-2c90b7315224_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous in-frame deletion Lys232del occurs at the end of an exon and is predicted to result in a splice site loss, leading to a mRNA frameshift and subsequently to a premature termination codon. However, a splice defect was not confirmed.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/276e718b-5d1e-4612-9a88-648aeb07b9bb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","rdfs:label":"Case 3: Patient B-IV:4","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":2,"detectionMethod":"WES","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0011100","obo:HP_0003049","obo:HP_0011229","obo:HP_0001272","obo:HP_0002650","obo:HP_0000455","obo:HP_0001250","obo:HP_0001838","obo:HP_0011800","obo:HP_0003066","obo:HP_0012385","obo:HP_0000431","obo:HP_0000565","obo:HP_0000369","obo:HP_0000463","obo:HP_0001263","obo:HP_0001539","obo:HP_0001500","obo:HP_0000324","obo:HP_0001377","obo:HP_0002187","obo:HP_0006118","obo:HP_0200021","obo:HP_0002079","obo:HP_0000319","obo:HP_0012811","obo:HP_0010801","obo:HP_0000470","obo:HP_0010306","obo:HP_0009937","obo:HP_0001376","obo:HP_0006143","obo:HP_0012810","obo:HP_0000592","obo:HP_0000684","obo:HP_0005306","obo:HP_0010851","obo:HP_0006610","obo:HP_0100876","obo:HP_0000175","obo:HP_0200055","obo:HP_0001561","obo:HP_0001357","obo:HP_0002236","obo:HP_0003121","obo:HP_0002557","obo:HP_0001212","obo:HP_0000481","obo:HP_0000219","obo:HP_0010747","obo:HP_0200005","obo:HP_0000343","obo:HP_0009795","obo:HP_0000465","obo:HP_0001181","obo:HP_0001508","obo:HP_0001257","obo:HP_0000316","obo:HP_0000308","obo:HP_0002521","obo:HP_0000356","obo:HP_0001762","obo:HP_0000179"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6c0c8e3c-7d0b-434b-b410-2c90b7315224_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","allele":{"id":"https://genegraph.clinicalgenome.org/r/fddaac8e-420f-4b8c-b3e4-ddb44e0e4916","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.695_697del (p.Lys232del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139532586"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8c2bb03d-6c39-4fb1-a512-8b6e67624937_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous c.1414-1G>C splice variant was confirmed, by cDNA analysis, to cause an absence of normal mRNA product with presence of three aberrant isoforms: one with exon 15 skipped, one with 76 bases of intron 14 retained and one with the first seven bases of exon 15 deleted.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/860aeb52-5575-4bda-a803-8bada6054f1f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","rdfs:label":"Case 1: Patient A-III:1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"detectionMethod":"WES with Sanger confirmation","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001377","obo:HP_0002510","obo:HP_0003121","obo:HP_0002187","obo:HP_0001357","obo:HP_0001344","obo:HP_0002650","obo:HP_0008936","obo:HP_0001263","obo:HP_0003066","obo:HP_0000817","obo:HP_0002521","obo:HP_0000175","obo:HP_0002179","obo:HP_0011097"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/8c2bb03d-6c39-4fb1-a512-8b6e67624937_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","allele":{"id":"https://genegraph.clinicalgenome.org/r/77a0ad9e-3f24-4f9f-8e07-120009a1d9ce","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.1414-1G>C (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA349268017"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1dcc7888-5723-4c37-a93d-47d321837656_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The compound heterozygous variants Leu284Phe and c.83-3T>C were considered putative disease causing variants, however no functional evidence was provided. The c.83-3T>C variant is present in the gnomAD Non-Finnish European population at a MAF of 0.000009200 (1/108698 alleles).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5ce6c380-3812-4f2b-acbd-5e73c895f5ba","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31144778","rdfs:label":"65: MR2053","detectionMethod":"Coding sequences and nearest flanking regions of 74 genes, associated with ID, were targeted for deep sequencing with a custom Ampliseq panel assay.","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0001249","obo:HP_0001250","obo:HP_0001251"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1dcc7888-5723-4c37-a93d-47d321837656_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31144778","allele":[{"id":"https://genegraph.clinicalgenome.org/r/08649a4f-a749-4787-ad2e-580a983a25bc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.850C>T (p.Leu284Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1962747"}},{"id":"https://genegraph.clinicalgenome.org/r/73028447-402c-40e6-b47d-ee0fedf20d49","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.83-3T>C (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1962509"}}]}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/45e041a5-94b4-43fe-a980-e04370f824c6_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous missense variant Ser12Cys may produce subtle effects on cellular localisation, protein-protein interactions and/or protein processing, with a subsequent effect on GABA production, however no functional evidence was provided. The variant is present in gnomAD at an MAF of 0.0001633 (5/30616 alleles) in the South Asian population.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/659c13fc-b492-4425-a8bc-12ba37c954d3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15571623","rdfs:label":"4578","detectionMethod":"GAD1 exon sequences were amplified by PCR and sequenced by cycle sequencing.","firstTestingMethod":"PCR","phenotypes":["obo:HP_0002827","obo:HP_0100021","obo:HP_0006380","obo:HP_0003487","obo:HP_0001276","obo:HP_0000565","obo:HP_0010864","obo:HP_0001347","obo:HP_0001257"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/45e041a5-94b4-43fe-a980-e04370f824c6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15571623","allele":{"id":"https://genegraph.clinicalgenome.org/r/f2501562-e00e-4ad3-8ed6-b634999b3863","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.35C>G (p.Ser12Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA117237"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/29e0199d-e20b-4abe-b62a-119854a0618d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous missense variant Phe324Cys is predicted to cause a reduction in protein stability, however no functional evidence was provided. The variant occurs the the gnomAD South Asian population at an MAF of 0.00006534 (2/30610 alleles).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/157efebc-bef3-48e8-a144-5255b7defd88","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","rdfs:label":"B:III-4","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0010864","obo:HP_0001348","obo:HP_0001999","obo:HP_0001263","obo:HP_0011182","obo:HP_0001713","obo:HP_0000733","obo:HP_0002069","obo:HP_0001371"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/29e0199d-e20b-4abe-b62a-119854a0618d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","allele":{"id":"https://genegraph.clinicalgenome.org/r/dc9d39fe-3cc0-4dcd-8cae-c6cb08aa0b82","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.971T>G (p.Phe324Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1962796"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4fa73b06-b800-4aeb-9cc0-c5e14a7d5a51_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous missense variant Glu509Lys affects an evolutionarily extremely well-conserved residue within the pyridoxal-dependent decarboxylase conserved domain, indicating that the variant may damage protein function. However, no functional evidence was provided.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/462fe041-c92f-42d6-abb4-0533840edea4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","rdfs:label":"Case 11: Patient F-IV:1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001347","obo:HP_0001264","obo:HP_0001344","obo:HP_0006956","obo:HP_0001250","obo:HP_0010851","obo:HP_0002187","obo:HP_0003121","obo:HP_0001272","obo:HP_0001332","obo:HP_0001263","obo:HP_0011174","obo:HP_0001239","obo:HP_0003487"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/4fa73b06-b800-4aeb-9cc0-c5e14a7d5a51_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","allele":{"id":"https://genegraph.clinicalgenome.org/r/499f5133-0bdc-4119-8db2-11c70be0726a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.1525G>A (p.Glu509Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA349268905"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/538254e1-ab7b-4028-8b64-4b337617145f_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous missense variant Asn564Ser is predicted to cause a reduction in protein stability, however no functional evidence was provided. The variant occurs the the gnomAD non-Finnish European population at an MAF of 0.000008796 (1/113694 alleles).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4fa49cda-4e5b-4eff-946d-ca9d166fe656","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","rdfs:label":"A:III-2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0030084","obo:HP_0001250","obo:HP_0001763","obo:HP_0011003","obo:HP_0001263","obo:HP_0010851","obo:HP_0001252","obo:HP_0001999","obo:HP_0000787","obo:HP_0002342","obo:HP_0002650","obo:HP_0000126","obo:HP_0000121"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/538254e1-ab7b-4028-8b64-4b337617145f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","allele":{"id":"https://genegraph.clinicalgenome.org/r/ad8d1fb2-80ef-4b8d-b10e-bd1f7af8f3bb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.1691A>G (p.Asn564Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA349269989"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/04c86edb-f75d-4a75-bcb3-779b4441cac5_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous nonsense variant Arg531Ter occurs in the final 50bp of the penultimate exon, as such NMD is not predicted to occur and no evidence has been provided regarding the function of a truncated protein. Of note, Case 9: Patient E-III:2 is also homozygous for this nonsense variant and given the relative geographical proximity, a common haplotype is possible.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/088bccd8-e058-435b-8222-4960e171dbd0","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","rdfs:label":"Case 7: Patient D-V:2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"detectionMethod":"WGS with Sanger confirmation.","firstTestingMethod":"Whole genome shotgun sequencing","phenotypes":["obo:HP_0008936","obo:HP_0002123","obo:HP_0001263","obo:HP_0002353","obo:HP_0002187","obo:HP_0011097","obo:HP_0002521","obo:HP_0001332","obo:HP_0001257","obo:HP_0002650","obo:HP_0012704"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/04c86edb-f75d-4a75-bcb3-779b4441cac5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","allele":{"id":"https://genegraph.clinicalgenome.org/r/5fa4b037-6c32-4063-aa4c-28a9671731ef","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.1591C>T (p.Arg531Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1962995"}}}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/204df913-2454-4208-98c0-a77d70dd8157_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The compound heterozygous variants Leu224SerfsTer5 (maternal) in exon 7 and Arg531Ter (not maternal) in exon 16 of 17 both cause premature stop codons, however only the frameshift is predicted to result in NMD.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0c68cf57-3717-446f-97d8-97816b1626d4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","rdfs:label":"C:II-1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0011470","obo:HP_0001263","obo:HP_0002069","obo:HP_0200136","obo:HP_0010864","obo:HP_0001252","obo:HP_0011182","obo:HP_0001264","obo:HP_0010851","obo:HP_0002421","obo:HP_0001344"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/204df913-2454-4208-98c0-a77d70dd8157_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","allele":[{"id":"https://genegraph.clinicalgenome.org/r/5fa4b037-6c32-4063-aa4c-28a9671731ef"},{"id":"https://genegraph.clinicalgenome.org/r/b86455b8-a206-49aa-a966-3fa06cb63c11","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.670del (p.Leu224SerfsTer5)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139532588"}}]}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/96086587-6bd0-4389-be53-824562a76687_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous missense variant Trp468Gly was identified in this patient, with no functional evidence provided.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/85a39fcc-56ed-4c3a-8d8a-bdef3d99dd3f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28454995","rdfs:label":"Case 43","detectionMethod":"WES","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0100021","obo:HP_0002123","obo:HP_0001999","obo:HP_0001263","obo:HP_0001252","obo:HP_0002510"],"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/96086587-6bd0-4389-be53-824562a76687_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28454995","allele":{"id":"https://genegraph.clinicalgenome.org/r/135c23c5-57e1-420d-823c-812dc0d53838","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.1402T>G (p.Trp468Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/800908"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/82e4b7d7-97f7-492e-a771-94dd280c1b6a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The homozygous missense variant Thr347Met is predicted to cause a reduction in protein stability, in association with a break in H-bonds in the pyridoxal 5â€²-phosphate binding domain. However, no functional evidence was provided. The variant occurs the the gnomAD Latino population at an MAF of 0.00002891 (1/34590 alleles).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/adec6289-e47b-4964-b552-317c84b4244a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","rdfs:label":"D:II-4","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"detectionMethod":"WES with Sanger confirmation.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"short arms","phenotypes":["obo:HP_0001999","obo:HP_0002015","obo:HP_0002521","obo:HP_0001540","obo:HP_0010864","obo:HP_0001252","obo:HP_0011097","obo:HP_0001263"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/82e4b7d7-97f7-492e-a771-94dd280c1b6a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32705143","allele":{"id":"https://genegraph.clinicalgenome.org/r/366893d7-bb8b-4e4b-a001-c273fdaac61a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000817.3(GAD1):c.1040C>T (p.Thr347Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA60560957"}}}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/20fdee08-81b0-4957-a18a-8f622e0ab054_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/677b2494-a414-46b5-9448-b20cedcc97ee_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","rdfs:label":"Family A","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/677b2494-a414-46b5-9448-b20cedcc97ee","type":"Family","rdfs:label":"Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/860aeb52-5575-4bda-a803-8bada6054f1f"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000817","obo:HP_0011097","obo:HP_0001344","obo:HP_0002187","obo:HP_0003066","obo:HP_0001263","obo:HP_0001377","obo:HP_0003121","obo:HP_0008936","obo:HP_0000175"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/860aeb52-5575-4bda-a803-8bada6054f1f"}},{"id":"https://genegraph.clinicalgenome.org/r/b8d78b72-59dc-447d-a3ea-1435bbfb74ab_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15571623","rdfs:label":"Family B","family":{"id":"https://genegraph.clinicalgenome.org/r/b8d78b72-59dc-447d-a3ea-1435bbfb74ab","type":"Family","rdfs:label":"Family B","member":{"id":"https://genegraph.clinicalgenome.org/r/659c13fc-b492-4425-a8bc-12ba37c954d3"}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0100021","obo:HP_0001347","obo:HP_0003487","obo:HP_0001257"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/659c13fc-b492-4425-a8bc-12ba37c954d3"},"publishedLodScore":2.6,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/2ca6e01e-280c-4c80-bd46-415c3a27ba32_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","rdfs:label":"Family C","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/2ca6e01e-280c-4c80-bd46-415c3a27ba32","type":"Family","rdfs:label":"Family C","member":{"id":"https://genegraph.clinicalgenome.org/r/6a392e44-bd6d-48a3-a0c8-3e83c7aeb467"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002509","obo:HP_0002187","obo:HP_0000175","obo:HP_0010851","obo:HP_0001250"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/6a392e44-bd6d-48a3-a0c8-3e83c7aeb467"}},{"id":"https://genegraph.clinicalgenome.org/r/a8af2804-5ac0-44dc-8b95-41e2a8b50097_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32282878","rdfs:label":"Family D","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/a8af2804-5ac0-44dc-8b95-41e2a8b50097","type":"Family","rdfs:label":"Family D","member":{"id":"https://genegraph.clinicalgenome.org/r/088bccd8-e058-435b-8222-4960e171dbd0"}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002187","obo:HP_0002353","obo:HP_0002123","obo:HP_0008936","obo:HP_0011097","obo:HP_0001257","obo:HP_0001332","obo:HP_0001263"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/088bccd8-e058-435b-8222-4960e171dbd0"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":2781,"specifiedBy":"GeneValidityCriteria7","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Woy1f-1RvWw","type":"GeneValidityProposition","disease":"obo:MONDO_0016021","gene":"hgnc:4092","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_20fdee08-81b0-4957-a18a-8f622e0ab054-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}